Previous studies have revealed that the signal transduction system plays crucial roles in osteosarcoma development, and molecules in signaling pathways are being evaluated as therapeutic targets, including those in the receptor activator for nuclear factor‐kB (RANK), Wnt, Notch, phosphatidylinositol 3‐kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and mechanotransduction pathways 5. This evidence concerns the gene TNFRSF11A and osteosarcoma.